

# **Press Release**

# Capsulution signs cooperation agreement with Schering and AcriTec

Berlin based company develops new products in the field of the nanoparticle based delivery of active substances.

**Berlin, April 18<sup>th</sup> 2006** - In March the Capsulution NanoScience AG, a Berlin based nanotechnology company that is specialised in the development of intelligent "packaging" systems for active substances has signed a cooperation agreement with Schering AG and Acri.Tec GmbH. The cooperation project is supported by the German Federal Ministry of Education and Research (BMBF). Goal of the cooperation is the development of advanced drug delivery systems designed for a more effective application of drugs.

Within the next three years, the companies will concentrate on special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hytro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.

Two different indications of pharmacotherapy are within the focus of the development cooperation. One application is the contraception and treatment of various gynaecological diseases. And the other application is the therapy of retinal removal. Both application areas have special demands for drug-delivery-systems, but pursue the similar approach to nano-functional hydro-gels (NanoGel). The challenge of the cooperation is to determine the exact specification of hydro-gel and nanoparticle characteristics and to establish appropriate in-vitro systems.

The cooperation processes all interdisciplinary aspects from the research of polymers, development of drug-delivery-systems, clinical developments up to the manufacture of products. In this context there are further German research partners included to the project such as the Fraunhofer Institute for Applied Polymer Research IAP, the University of Regensburg and the ITEMP of the medical department of the Aachen University of Technology.

#### About Acri.Tec

Acri.Tec GmbH is a company that develops innovative products in the field of ophthalmic surgery. The label "made in Germany" stands for best quality with high international acceptance. The product range primary includes intraocular lenses (substitute lenses for eye cataract patients), as well as other implants, hygienic fluids, surgical diamond-knifes, tools and other innovative special products. In 2001 the Acri.Tec GmbH was awarded by the states of Berlin and Brandenburg with the special Innovation-Award.





### **Contact person**

## **Schering AG**

Dr. Sascha General, Drug Delivery Systems, Pharmaceutical Development

Tel.: +49 (0) 30 4 6 81 76 55

Email: <a href="mailto:sascha.general@schering.de">sascha.general@schering.de</a>

#### Acri.Tec GmbH

Dr. D. Streufert Neuendorfstr. 20a 16761 Hennigsdorf

Tel.: 03302 202 6140 Fax: 03302 202 6115 d.streufert@acritec.de

#### **Capsulution Nanoscience AG**

Herr Dipl.-Kfm. Alexander Herrmann E-Mail: alexander.herrmann@capsulution.com

Telefon: +49 (0)30-63 92 36 00 Fax: +49 (0)30-63 92 36 01

alexander.herrmann@capsulution.com

# **About Capsulution NanoScience AG**

Capsulution NanoScience AG is a leading nanotechnolopy company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on nano-sized capsules. The company applies its worldwide-patented socalled LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulution has recently designated a Japanese licensee as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulution's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year's "Product Differentiation Innovation Award" in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Press Release and Press Box online:

http://www.pressebox.de/pressefach/capsulution-nanoscience-ag

